CROs/Service Providers

PPD launches Rare Disease and Pediatric Center of Excellence

Tuesday, February 28, 2017

Pharmaceutical Product Development (PPD) has established a Rare Disease and Pediatric Center of Excellence to oversee all rare disease and pediatric-related drug development activities. This new center of excellence provides pharmaceutical and biotechnology clients with a dedicated team of professionals focused on the design and execution of clinical trials that address the unique strategic, operational, medical and scientific challenges of clinical studies in rare disease and pediatric patient populations.

[Read More]

INC Research adds investigator payment offering

Thursday, February 23, 2017

INC Research, a global phase I to IV CRO, has announced expansion of its Functional Service Provider (FSP) service offering to include investigator payment processing, leveraging the company’s extensive expertise and delivery of customized solutions in this area as well as insights gained from its industry-recognized site relationships. The addition of investigator payment processing to the company’s FSP offering builds on its nearly 20 years of experience in meeting the needs of biopharmaceutical customers worldwide for standalone outsourced services under an FSP model, including Data Management, Medical Writing, Safety and Pharmacovigilance, and Site Contracts.

[Read More]

RCSI, Almac partner on target therapy-resistant cancer tumors

Wednesday, February 15, 2017

RCSI (Royal College of Surgeons in Ireland) and Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, have announced a major research collaboration that aims to gain a new understanding of how to target tumor cells that are resistant to cancer therapies and cause cancer to spread to other parts of the body. The project will explore the potential of a drug, based on initial research by RCSI’s Professor Tracy Robson and developed by Almac Discovery, which is currently undergoing a phase I dose escalation trial for patients with solid tumors. It is expected that the trial will be expanded in a biomarker selected patient population within ovarian cancer, however the drug, ALM201, has the potential to treat a range of other cancers.

[Read More]